Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease

NCT02833792 is registered in ClinicalTrials.gov with Stemedica Cell Technologies, Inc. as lead sponsor.

NCT NCT02833792
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02833792 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Study of Allogeneic Human Mesenchymal Stem Cells in Subjects With Mild to Moderate Dementia Due to Alzheimer's Disease
Lead sponsor
Stemedica Cell Technologies, Inc.
Phase
Phase 2
Overall status
Unknown status
Start date
June 1, 2016
Completion date
December 31, 2024
Enrollment
40 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

alzheimer dementia